Search
Levobunolol
go.drugbank.com/drugs/DB01210ApprovedA nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.
Rifaximin
go.drugbank.com/drugs/DB01220ApprovedInvestigationalRifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered
Synonyms: Rifamycin L 105, Rifamycin L 105SVProducts: RIFAXIGAL® 100MG/5ML POLVO PARA RECONSTITUIR A SUSPENSION ORAL13-deoxydoxorubicin
go.drugbank.com/drugs/DB05706InvestigationalGPX-100 is an anthracycline anticancer drug that belongs to the family of drugs called antitumor antibiotics.
Gantacurium
go.drugbank.com/drugs/DB05710InvestigationalGantacurium chloride is a new, investigational, non-depolarizing ultra-short acting neuromuscular blocker. It is being developed by Avera Pharmaceuticals.
Elesclomol
go.drugbank.com/drugs/DB05719InvestigationalElesclomol is a novel, injectable, drug candidate that kills cancer cells by elevating oxidative stress levels beyond a breaking point, triggering programmed cell death. … In preclinical models elesclomol showed potent killing of a broad range of cancer cell types at high doses, and an ability to strongly enhance the efficacy of certain chemotherapy agents, with minimal
AD 337
go.drugbank.com/drugs/DB05725InvestigationalAD 337 was under investigation in clinical trial NCT00377039 (A Multicentre Trial to Determine the Efficacy and Safety of AD-337 in the Treatment of Fibromyalgia).
AVI-5126
go.drugbank.com/drugs/DB05726InvestigationalAVI-526 works by silencing a gene known as c-myc, a key regulatory gene involved in cardiovascular restenosis.
CYT006-AngQb
go.drugbank.com/drugs/DB05739InvestigationalCYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. … It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient dosing schedules due to the long-lasting effect induced by vaccination.
Drinabant
go.drugbank.com/drugs/DB05750InvestigationalAVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant. It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being develop...
VSF-173
go.drugbank.com/drugs/DB05753InvestigationalStudy shows that VSF-173 possesses a novel mechanism to address disorders of excessive sleepiness. … It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression patterns suggestive of a stimulant effect.